Israel’s BrainStorm says stem cell drug benefits most patients in ALS trial – Reuters

Israel's BrainStorm says stem cell drug benefits most patients in ALS trialReutersShares in the company, which is also developing stem cell treatments for multiple sclerosis and Parkinson's disease, have nearly doubled in the past two sessions on Nasdaq in anticipation of the trial's results. The stock has nearly tripled in the past ...BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly ...MarketWatchall 2 news articles
http://blog.zandcell.com/israels-brainstorm-says-stem-cell-drug-benefits-most-patients-in-als-trial-reuters-2/